A phase II study of systemic chemotherapy with Docetaxel, CDDP, and S-1 followed by surgery in advanced gastric cancer with extensive lymph node metastasis(JCOG1002, BulkyGC Pre-DCS Phase II) - A phase II study of systemic chemotherapy with Docetaxel, CDDP, and S-1 followed by surgery in advanced gastric cancer with extensive lymph node metastasis(JCOG1002, BulkyGC Pre-DCS Phase II)

Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 50 人开始时间: 2011年7月29日最近更新: 2023年10月17日

试验速览

暂无简介。

•"1) Synchronous or metachronous (within 5 years) malignancies other than carcinoma in situ or mucosal cancer. 2) Women during pregnancy or breast-feeding. 3) Severe mental disease. 4) Under treatment with systemic steroid. 5) HBs antigen positive. 6) Under treatment with flucytosine, phenytoin, or warfarin. 7) Allergy to iodine. 8) History of hypersensitivity to DOC, CDDP, or polysorbate 80. 9) Peripheral motor neuropathy or peripheral sensory neuropathy by any reason. 10) Edema of limbs and trunk by any reason. 11) Interstitial pneumonia, pulmonary fibrosis, or severe emphysema. 12) Active bacterial or fungal infection. 13) Past history of myocardial infarction or unstable angina pectoris within 6 months. 14) Uncontrollable hypertension. 15) Uncontrollable diabetes mellitus or routine administration of insulin."

发起方

Japan Clinical Oncology Group (JCOG)